|
|
 |
|
Viewing report
|
|
|
|
Global Migraine Therapeutics Market: Market Forecast, Patient Flow, Competitive Landscape, and Pipeline Analysis
Commercial Insights, July 2011, Pages: 108
The new report from Commercial Insights, ‘Global Migraine Therapeutics Market: Market Forecast, Patient Flow, Competitive Landscape, and Pipeline Analysis', provides in-depth analysis of the current and future migraine market landscape globally. The report covers all aspects of the migraine therapeutics market for the US, Germany, France, UK, Spain, Italy, and Japan. It includes migraine therapeutics market forecasts, patient flow, epidemiology analysis, diagnosis rate analysis, treatment rate analysis, patient forecast, current competition, future competitive landscape, unmet need, and pipeline analysis. The report also provides insights in to the market events that impact the migraine therapeutics market by geography, and detailed clinical insights of high potential migraine therapies in the pipeline.
Market Update:
By the end of 2018, the migraine therapeutics market in the US, Germany, France, UK, Spain, Italy, and Japan will earn revenues of $4.5 billion, increasing at a compounded annual growth rate of 2.7% between 2010 and 2018. This positive market growth will be largely attributed to the launch and rapid uptake of new therapies such as Telcagepent. However, generic erosion of Rizatriptan, Zolmitriptan, and Topiramate will negatively impact the market.
Merck & Co's Telcagepant is poised to be the next market leader to drive the global migraine therapeutics market. Telcagepant will gain wider acceptance among the patient and physician population resulting in greater use. Key opinion leaders are enthusiastic about the expected launch and contribution of Telcagepant to the significant growth of migraine therapeutics market. Also, the need for better efficacious medication will drive its uptake.
The US will remain the largest market in 2018 with 79% market share. The market will benefit from favorable population demographics. Pharmaceutical companies should center their attention towards research and development activities, and sustaining their product's market share.
Scope of the Report:
- Geographies Covered: The US, Germany, France, UK, Spain, Italy, and Japan
- Forecast Period: 8 Years (2010 to 2018)
Key Features of the Report:
Market Analysis
- Migraine therapeutics market size and forecast by geography
- Insights into market events that impact the migraine therapeutics market by geography
- Leading therapies by geography
Competitive Landscape Analysis
- Market share insights of leading brands in the global migraine therapeutics market
- Future market share analysis of the global migraine therapeutics market
- Profiles of leading brands and their market shares
Patient Flow Analysis
- Patient flow study with diagnosis rate and treated population rate by geography
- Analysis and forecasts of migraine prevalence population by geography
- Analysis and forecasts of migraine diagnosis rate by geography
- Analysis and forecasts of migraine treatment rate by geography
Unmet Need
- Unmet need analysis of the global migraine therapeutics market
Pipeline Analysis
- Analysis of migraine pipeline molecules by phase of development
- Detailed clinical profiles of high potential phase 3 molecules
Key Words: Migraine, Therapeutics, Market Size, US, Global, Spain, Italy, France, Spain, Germany, Japan, UK, Forecast, Size, Forecasts, Patient, Flow, Competition, Landscape, Competitive, Diagnosis, Epidemiology, Prevalence, Rate, Treatment, Drugs, Chemotherapies, 2010, 2018, Pipeline, Clinical, Trials, Phase I, Phase II, Phase III
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
